The diagnosis and medical management of advanced neuroendocrine tumors.
The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
In the citing paper
“Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71-73).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
The Complex of Myxomas, Spotty Pigmentation, and Endocrine Overactivity
CARNEY, J. A., GORDON, H., CARPENTER, P. C., SHENOY, B. V., & W. GO, V. L. (1985) · Medicine · doi:10.1097/00005792-198507000-00007 · Cited by 1,114
Research works printed but not linked: 3
- Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
- Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
- Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305
Cited by
Items 301–400 of 679
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
Sowa‐Staszczak, A., Chrzan, R. M., Pach, D., Stefańska, A., Tomaszuk, M., Buziak‐Bereza, M., Kołodziej, M., Przybylik‐Mazurek, E., & Hubalewska–Dydejczyk, A. (2012) · Clinical Imaging · doi:10.1016/j.clinimag.2011.11.005 · Cited by 11
Pheochromocytoma: An Update on Risk Groups, Diagnosis, and Management
Nguyen-Martin, M. A., & Hammer, G. D. (2006) · Cited by 12
Cross sectional and nuclear medicine imaging of pancreatic insulinomas
Rayamajhi, S. J., Lee, J., Mittal, B. R., Jessop, A., Chasen, B., & Bhosale, P. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0904-7 · Cited by 12
Baptiste, G. G., Postlewait, L. M., Ethun, C. G., Le, N., Russell, M. C., Kooby, D. A., Staley, C. A., Maithel, S. K., & Cardona, K. (2016) · The American Surgeon · doi:10.1177/000313481608200731 · Cited by 11
Kulke, M. H., Benson, A. B., Dasari, A. N., Huynh, L. Y., Cai, B., Totev, T. I., Roesner, N., Duh, M. S., Neary, M. P., Maurer, V. E., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0519 · Cited by 11
“Functional NET tumors cause distinct syndromes such as carcinoid syndrome (CS) because of secreted peptides and neuroamines [4].”
BackgroundFunctional Imaging of Neuroendocrine Tumors
Binnebeek, S. V., Karges, W., & Mottaghy, F. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-062-1_7 · Cited by 11
Nicolaou, A., Thomas, D., Alexandraki, K., Sougioultzis, S., Tsolakis, A. V., & Kaltsas, G. (2014) · Neuroendocrinology · doi:10.1159/000362879 · Cited by 13
Self-citationPancreatic paraganglioma - a rare and dangerous entity. Vascular anatomy and impact on management
Straka, M., Soumarová, R., Migrová, M., & Vojtek, C. (2014) · Journal of Surgical Case Reports · doi:10.1093/jscr/rju074 · Cited by 11
“In case of an inoperable tumour with malignant behaviour, chemotherapy or therapy with radionucleotides may be used [6, 7].”
BackgroundInternational Practice Patterns and Resource Utilization in the Treatment of Neuroendocrine Tumors
Casciano, R., Wang, X., Stern, L. S., Parikh, R. C., Chulikavit, M., Willet, J., Liu, Z., Strosberg, J., Cadiot, G., & Riechelmann, R. P. (2013) · Pancreas · doi:10.1097/mpa.0b013e31826707cc · Cited by 11
“Althoughmany symptoms associated with NET can derive from tumor bulk as the disease progresses, neuroendocrine cells have the ability to secrete metabolically active substances, and therefore, NETs can also cause a variety of distinct clinical syndromes such as hyperinsulinemia or carcinoid syndrome.(4) The necessary…”
Background68 Ga-DOTA-TATE—a source of eye lens exposure for nuclear medicine department workers
Wrzesień, M., & Albiniak, Ł. (2018) · Journal of Radiological Protection · doi:10.1088/1361-6498/aaea8e · Cited by 11
Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm
Karakaxas, D., Gazouli, M., Liakakos, T., Vaiopoulou, A., Apessou, D., Papaparaskeva, K., Patapis, P., & Dervenis, C. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000138 · Cited by 11
Budek, M., Nuszkiewicz, J., Piórkowska, A., Czuczejko, J., & Szewczyk‐Golec, K. (2022) · Biomedicines · doi:10.3390/biomedicines10102660 · Cited by 10
“Simultaneous determination of CgA and NSE has been shown a higher sensitivity than the independent determination of each of these parameters [41].”
BackgroundLiu, L., Liu, W., Jia, Z., Li, Y., Wu, H., Qu, S., Zhu, J., Liu, X., & Xu, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20928 · Cited by 10
“In recent years, with the popularization of physical examination and the improvement of detection methods (CT and endoscopy), the detection rate of gastric NENs has increased from 7-fold to 10-fold [8,9].”
Kolesnikova, G. S., Лапшина, А. М., Voronkova, I. А., Marova, E. I., Arapova, S., Goncharov, N. P., & Dedov, I. I. (2013) · International Journal of Endocrinology · doi:10.1155/2013/659232 · Cited by 10
“Enhanced expression of Ki-67 suggests more active proliferation in EAS tumours [11].”
BackgroundResultNejjari, M., Kryza, D., Poncet, G., Roche, C., Perek, N., Chayvialle, J., Bars, D. L., Scoazec, J., Janier, M. F., & Borson‐Chazot, F. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.09.008 · Cited by 10
“However, its sensitivity may be limited for small and/or dedifferentiated tumors [3].”
BackgroundSpada, F., Rossi, R. E., Kara, E., Laffi, A., Massironi, S., Rubino, M., Grimaldi, F., Bhoori, S., & Fazio, N. (2021) · Pharmaceuticals · doi:10.3390/ph14060539 · Cited by 10
“Around 80% of patients with CS present a chronic secretory diarrhea due to specific hormones that influence the GI motility inducing more than three bowel movements per day [27].”
BackgroundGur, C., Lalazar, G., Salmon, A. Y., Dubiner, V., & Gross, D. J. (2007) · Pituitary · doi:10.1007/s11102-007-0053-7 · Cited by 10
“These tumors are either diagnosed incidentally or due to symptoms of local pressure caused by an expanding mass or metastases [2].”
Síndromes hormonales paraneoplásicos
Forga, L., Anda, E., & de Esteban, J. P. M. (2005) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272005000300006 · Cited by 15
Exploring new frontiers in molecular imaging: Emergence of68Ga PET/CT
Tan, E. H., & Goh, S. W. (2010) · World Journal of Radiology · doi:10.4329/wjr.v2.i2.55 · Cited by 10
Park, J. Y., Lee, T. S., Choi, T.-H., Cheon, G. J., Choi, C.-W., & Awh, O.-D. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.016 · Cited by 10
Resistance of neuroendocrine tumours to somatostatin analogs
Angelousi, A. G., Koumarianou, A. A., Chatzellis, E., & Kaltsas, G. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166488 · Cited by 9
“Τhese properties also apply to neuroendocrine cells that in addition have the ability to synthesize and secrete bioactive substances, peptides and amines, causing distinctive secretory syndromes (functioning tumors) [2].”
BackgroundSelf-citationA rare paraganglioma with skull and brain metastasis
Zhang, L., Li, F., Zhang, Y., & Zhu, S. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.06.043 · Cited by 9
Katalinić, D., Šantek, F., Juretić, A., Škegro, D., & Pleština, S. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-358 · Cited by 9
Albu, A. I., Zirnea, A., Georgescu, O., Terzea, D. C., Jinga, D.-C., & Fica, S. V. (2008) · PubMed Central · Cited by 9
Krawczyk, A., Hasse-Lazar, K., Pawlaczek, A., Szpak‐Ulczok, S., Krajewska, J., Paliczka-Cieślik, E., Jurecka‐Lubieniecka, B., Roskosz, J., Chmielik, E., Ziaja, J., et al. (2010) · PubMed · Cited by 12
123I-labeled metaiodobenzylguanidine for diagnosis of neuroendocrine tumors
Cheng, Z. (2009) · Reports in Medical Imaging · doi:10.2147/rmi.s4529 · Cited by 9
Li, Y., Chi, F.-L., Wang, S., Wang, W., Yang, J., & Huang, Y.-B. (2012) · Case Reports in Otolaryngology · doi:10.1155/2012/941065 · Cited by 9
Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm
Ye, L., Santarpia, L., & Gagel, R. F. (2009) · Endocrine Practice · doi:10.4158/ep09148.rar · Cited by 9
MEN1 family with a novel frameshift mutation
Nuzzo, V., Tauchmanovà, L., Falchetti, A., Faggiano, A., Marini, F., Piantadosi, S., Brandi, M. L., Leopaldi, L., & Colao, A. A. L. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344129 · Cited by 9
Balasubramanian, G., & Nellaiappan, V. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-203425 · Cited by 9
Carcinoid Syndrome With Angioedema and Urticaria
Bożek, A., Rachowska, R., Krajewska, J., Paliczka-Cieślik, E., Filipowska, B., & Jarząb, J. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.5.691 · Cited by 9
Tumores neuroendocrinos gastrointestinales y pancreáticos
Salazar, R., Villabona, C., & Fabregat, J. (2006) · Medicina Clínica · doi:10.1157/13091016 · Cited by 9
Luo, X., & Gao, Z. (2025) · Protein and Peptide Letters · doi:10.2174/0109298665359781250114055525 · Cited by 8
Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report
Behdadnia, A., & Jeddi, M. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-04042-5 · Cited by 8
“Neuroendocrine tumors (NETs) are uncommon and arise from the neuroendocrine cells that are distributed throughout the body and secrete active peptide and amine hormones that can manifest with variable clinical syndrome [8].”
BackgroundZhang, Y. C. (2011) · Oncology Letters · doi:10.3892/ol.2011.344 · Cited by 8
Duodenal neuroendocrine tumor and the onset of severe diabetes mellitus in a US veteran
Murray, L., Haley, C. L., Berry-Cabán, C. S., & Toledo, A. (2016) · SAGE Open Medical Case Reports · doi:10.1177/2050313x15624530 · Cited by 8
Narayan, A., Yan, Y., Lisok, A., Brummet, M. E., Pomper, M. G., Lesniak, W. G., Dannals, R. F., Merino, V. F., & Azad, B. B. (2019) · Oncotarget · doi:10.18632/oncotarget.27184 · Cited by 8
“Neuroendocrine neoplasms (NENs) are an extremely heterogenous group of malignancies with variable clinical behavior including hormonally active or inactive tumors that range from being well-differentiated and slow growing to poorly differentiated and aggressive [1, 2].”
BackgroundWhat Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
García‐Álvarez, A., Cubero, J. H., & Capdevila, J. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01235-x · Cited by 8
Management of neuroendocrine tumors: current and future therapies
Öberg, K. E. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.81 · Cited by 8
Endoscopic resection for gastrointestinal neuroendocrine tumors
Boškoski, I., Volkanovskа, A., Tringali, A., Bove, V., Familiari, P., Perri, V., & Costamagna, G. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.816117 · Cited by 8
Ectopic insulinomas in the pelvis secondary to rectum neuroendocrine tumour
Li, T.-N., Liu, Z., Zhang, Y., & Wang, F. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224281 · Cited by 8
Future perspectives on neuroendocrine tumors
Castellano, D., Salazar, R., & Raymond, É. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9294-z · Cited by 8
“Some biochemical markers that are identifiable in body fluids may suggest the presence of specific tumors, such as gastrin in gastrinomas and insulin in insulinomas, but other markers are common to several GEP-NET types, such as chromogranin-A, which is a precursor of several functional peptides secreted by neuroendoc…”
BackgroundLibé, R., & Chanson, P. (2007) · Annales d Endocrinologie · doi:10.1016/s0003-4266(07)80002-3 · Cited by 8
“[22] Kaltsas GA, Besser GM, Grossman AB.”
BackgroundJang, B. G., Kim, S. Y., & Park, S. (2009) · Pathology International · doi:10.1111/j.1440-1827.2009.02384.x · Cited by 8
Plenis, A., Miękus, N., Olędzka, I., Bączek, T., Lewczuk, A., Woźniak, Z., Koszałka, P., Seroczyńska, B., & Skokowski, J. (2013) · Molecules · doi:10.3390/molecules181012857 · Cited by 8
“imaging with endoscopic ultrasound and somatostatin receptor fusion imaging, although surgery remains the mainstay of NET treatment [7–10].”
MethodGrowth Hormone-Secreting Tumors: Genetic Aspects and Data from Animal Models
Lytras, A., & Tolis, G. (2006) · Neuroendocrinology · doi:10.1159/000095525 · Cited by 8
van Leeuwaarde, R. S., Clavijo, A. ́. G., Pracht, M., Емельянова, Г. С., Cheung, W. Y., Thirlwell, C., Öberg, K., & Spada, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051271 · Cited by 7
“Considering long-term survival, preservation of health-related quality of life (HR-QoL) has become a major priority [5].”
BackgroundSağer, S., Kabasakal, L., Ocak, M., Maëcke, H. R., Uslu, L., Halaç, M., Asa, S., Sağer, G., Önsel, Ç., & Kanmaz, B. (2013) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000006 · Cited by 7
Milione, M., Pusceddu, S., Gasparini, P., Melotti, F., Maisonneuve, P., Mazzaferro, V., de Braud, F., & Pelosi, G. (2012) · Cancers · doi:10.3390/cancers4030808 · Cited by 7
“A distinctive feature of INETs, especially when involving the liver, is their capability of causing distinct clinical syndromes [1,3,4], which can be faithfully monitored measuring the relevant hormones in the bloodstream.”
BackgroundTargeting histone deacetylases for combination therapies in neuroendocrine tumors
Gagliano, T., & Brancolini, C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00260-x · Cited by 7
Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica, H., Malecha-Jędraszek, A., Strosławska, E., Burska, A. N., & Szubstarski, F. (2011) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0088-x · Cited by 7
Malignant insulinoma misdiagnosed and treated as epilepsy
Louda, F., Chadli, A., Elaziz, S., Elghomari, H., & Farouqi, A. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.11.002 · Cited by 7
Baptiste, G. G., Postlewait, L. M., Ethun, C. G., Le, N., McInnis, M. R., Russell, M. C., Winer, J. H., Kooby, D. A., Staley, C. A., Maithel, S. K., et al. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24279 · Cited by 7
“High-grade NETs are characterized by marked necrosis and cellular atypia with a high proliferative status, representing a more aggressive tumor biology and leading to a rapid clinical course and poor overall survival in contrast to other GEP NETs [1].”
BackgroundClinical features of gastroenteropancreatic tumours
Gut, P., Czarnywojtek, A., Bączyk, M., Ziemnicka, K., Fischbach, J., Wrotkowska, E., & Ruchała, M. (2015) · Gastroenterology Review · doi:10.5114/pg.2015.52346 · Cited by 11
“Almost all insulinomas are located within the pancreas, even though aberrant cases have been described in the duodenum, ileum, lung, and cervix [1].”
BackgroundKos‐Kudła, B. (2006) · PubMed · Cited by 7
Chua, A., Perrin, A., Ricci, J. F., Neary, M. P., & Thabane, M. E. (2018) · Current Oncology · doi:10.3747/co.25.3532 · Cited by 7
Wang, Z., & Yang, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1763633 · Cited by 7
Circulatory collapse in a patient with gastrinoma after metoclopramide administration.
Lau, K. K., Chan, K. W., Lok, C. M., Lam, A. W., Lee, H. H., Luk, W., Mak, C. M., Ching, C., Lo, J., Li, S. M., et al. (2009) · PubMed · Cited by 7
Pallais, J. C., Blake, M. A., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmcpc1114037 · Cited by 6
Liu, F. F., Wang, C., XING, Y.-L., Wu, J., & Tang, Y. (2014) · Oncology Letters · doi:10.3892/ol.2014.2776 · Cited by 6
“A previous study revealed that carcinoid cells express a large number of somatostatin receptors, therefore, somatostatin analogs could be used as first‐line therapy drugs for patients (13).”
Surgical resection of hepatic and cardiac neuroendocrine metastases from a caecal primary tumour
Williamson, J., Anderson, J. R., & Spalding, D. R. C. (2014) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588414x13814021676954 · Cited by 6
“of enterochromaffin cells, which predominate in the gastrointestinal tract.(2) Approximately 7% of all gastrointestinal NETS arise in the colon and there is a right-sided predominance with a peak incidence in the sixth decade.”
BackgroundUpdate on medical treatment of small intestinal neuroendocrine tumors
Pusceddu, S., Femia, D., Russo, G. L., Ortolani, S., Milione, M., Maccauro, M., Vernieri, C., Prinzi, N., Concas, L., Leuzzi, L., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1207534 · Cited by 6
“For localization of both primary and metastatic lesions, functional imaging with radiolabelled somatostatin receptor analogs (SSAs) represents a sensitive imaging modality, able to provide information about tumor location, expression of various receptors, and radiotracer uptake and accumulation [15].”
BackgroundRanade, R. R., & Basu, S. K. (2015) · World Journal of Nuclear Medicine · doi:10.4103/1450-1147.172307 · Cited by 6
“Neuroendocrine tumors are known to secrete biologically active peptides and amines that produce distinct clinical symptoms.[8] HHM is a paraneoplastic syndrome occurring due to hypersecretion of parathyroid hormone-related protein (PTHrP) by the underlying tumor.”
Pífano, M., Garona, J., Sobol, N. T., Albertó, M., Alonso, D. F., & Ripoll, G. V. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0178 · Cited by 6
Studies on the Shipworms III : Pattern of Vertical Settlement of Shipworms
Tsunoda, K., & Nishimoto, K. (1978) · Kyoto University Research Information Repository (Kyoto University) · Cited by 6
Gastrointestinal Hormones and Tumor Syndromes
Taheri, S., Ghatei, M. A., & Bloom, S. R. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00152-0 · Cited by 6
Migut, A., Kaur, H., & Avritscher, R. (2020) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2020.08.002 · Cited by 6
Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms
Koumarianou, A. A., Kaltsas, G., Chatzellis, E., Kyriakopoulos, G., Kolomodi, D., & Alexandraki, K. (2021) · Endocrine · doi:10.1007/s12020-021-02639-8 · Cited by 6
Self-citationPrise en charge chirurgicale des tumeurs endocrines du tractus gastro-intestinal
Brunaud, L., Bresler, L., Ayav, A., Muresan, M., Klein, M., Weryha, G., & Boissel, P. (2004) · Annales de Chirurgie · doi:10.1016/j.anchir.2004.10.002 · Cited by 6
Endoscopic treatment of gastrointestinal carcinoid tumors
Park, Y. B., Kim, J. I., Ha, B. H., Cheung, D. Y., Kim, T. H., Kim, C. H., Kim, S. S., Cho, S. H., Park, S., Chae, H. S., et al. (2007) · The Korean Journal of Internal Medicine · Cited by 6
Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-Nets): A Review
Yi, C. C. X. (2013) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000154 · Cited by 6
“Functioning GEP-NETs become evident when a characteristic clinical syndrome secondary to the secretion of bioactive substances [49].”
BackgroundBolanowski, M., Kos‐Kudła, B., Rzeszutko, M., Marciniak, M., & Zatońska, K. (2006) · PubMed · Cited by 6
Metabolic changes in neuroendocrine neoplasms
Hu, C., Chen, L., Ding, Y., Ye, M., & Tang, Q. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05656-2 · Cited by 5
“The systemic therapies include somatostatin analogue therapy, chemotherapy, targeted therapies, interventional procedures, and radionuclide therapy, tailored to the individual’s specific condition and the extent of the disease [34, 35].”
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Tomassetti, P., Cevenini, M., Guidetti, E., Cacciari, G., Cipollini, M. L., Galassi, E., Fabbri, M. C., Nori, F., Campana, D., Corinaldesi, R., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.111 · Cited by 5
Ursprung, S., Zhang, M. L., Asmundo, L., Hesami, M., Najmi, Z., Cañamaque, L. G., Shenoy‐Bhangle, A. S., Pierce, T. T., Mojtahed, A., Blake, M. A., et al. (2024) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001593 · Cited by 5
Budek, M., Nuszkiewicz, J., Czuczejko, J., Maruszak, M., Wróblewska, J., Wojtasik, J., Hołyńska-Iwan, I., Pawłowska, M., Woźniak, A., & Szewczyk‐Golec, K. (2024) · Current Oncology · doi:10.3390/curroncol31100456 · Cited by 6
“Data in the literature show that the simultaneous measurement of CgA and NSE shows higher sensitivity and greater accuracy in predicting the prognosis and progression of the disease than the measurement of each of these parameters separately [12,13].”
BackgroundPruebas de imagen en el diagnóstico de los tumores neuroendocrinos
Díez, J. J., & Iglesias, P. L. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.04.048 · Cited by 5
“Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT.”
MethodInfluentialInsulinoma: Literature’s Review (2)
AlJadir, S. J. (2015) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2015.02.00031 · Cited by 5
“Pharmacologic doses (prednisone, approximately 1 mg/kg) must be used [60,75].”
MethodFeelders, R. A., Hofland, L. J., Kwekkeboom, D. J., Lamberts, S. W. J., & de Herder, W. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-375097-6.10035-6 · Cited by 5
Large cell neuroendocrine carcinoma in the unusual location of the descending colon
Cha, J.-W., Yang, M., & Mo, A. K. (2020) · Radiology Case Reports · doi:10.1016/j.radcr.2020.07.045 · Cited by 5
Herrera, M. F., Pantoja, J. P., Salazar, M. S., & Velázquez‐Fernández, D. (2009) · Springer eBooks · doi:10.1007/978-1-84628-881-4_41 · Cited by 5
“Scintigraphy using 111In-octreotide has shown to have a sensitivity of 67– 91% for the detection of ICT, and it is used for diagnosis, staging, and follow-up [40, 46, 47].”
BackgroundMethodTissera, N. S., Balconi, F., García‐Álvarez, A., Cubero, J. H., O’Connor, J. M., Chacón, M. F., & Capdevila, J. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102863 · Cited by 5
Hiperinsulinismo endógeno: revisão e seguimento de 24 casos
Felício, J. S., Martins, C. L. E. L. P., Semer, M., Kalinin, L. B., Nery, M., Machado, M. C. C., & Liberman, B. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000200001 · Cited by 7
Bearz, A., Lleshi, A., Perin, T., Fratino, L., Venturini, S., Giacalone, A., Sartor, I., Berretta, M., Sulfaro, S., & Tirelli, U. (2011) · Onkologie · doi:10.1159/000324669 · Cited by 5
Retroperitoneal paraganglioma presenting with pancytopenia: A rare case with rare manifestation
Ünver, M., Öztürk, Ş., Erol, V., Cartı, E. B., Bozbıyık, O., Kebapçı, E., Ölmez, M., & Akbulut, G. (2015) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2015.07.021 · Cited by 5
“Nonfunctional paragangliomas most commonly manifest as abdominal pain or a mass [4].”
BackgroundSanguansap, Y., Ruangpornvisuti, V. W., Tuntulani, T., Promarak, V., & Tomapatanaget, B. (2015) · RSC Advances · doi:10.1039/c5ra10321e · Cited by 5
PI(3)K–Akt–mTOR pathway as a potential therapeutic target in neuroendocrine tumors
Zitzmann, K., Vlotides, G., Göke, B., & Auernhammer, C. J. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.207 · Cited by 5
Sakhare, N., Das, S., Mathur, A., Mirapurkar, S., Paradkar, S., Sarma, H. D., & Sachdev, S. S. (2016) · RSC Advances · doi:10.1039/c6ra11217j · Cited by 5
Symington, M., Davies, L., Kaltsas, G., & Weickert, M. O. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-219692 · Cited by 5
Self-citationChicharro, P., Paniagua, A.-E., Rodríguez‐Jiménez, P., Ibañes, S., Cortina, B., Riveiro, J., Sampedro-Nuñez, M. A., Fraga, J., Marazuela, M., & Daudén, E. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14830 · Cited by 5
[18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome
Kok, J., Lin, M. F., Wong, V., Campbell, P., & Lin, P. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03428.x · Cited by 5
Starzyñska, T., Szawlowski, A. W., Kos‐Kudła, B., Królicki, L., Kunikowska, J., Nasierowska-Guttmejer, A. M., Rudzki, S., & Zgliczyński, W. (2008) · PubMed · Cited by 6
Fołtyn, W., Kos‐Kudła, B., Siemińśka, L., Zemczak, A., Strzelczyk, J., Marek, B., Kajdaniuk, D., Nowak, M., Borowska, M., & Jurecka‐Lubieniecka, B. (2006) · PubMed · Cited by 5
You, H., Sanli, Y., & Subramaniam, R. M. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.21067 · Cited by 6
Lopci, E., & Cistaro, A. (2013) · Springer eBooks · doi:10.1007/978-88-470-5358-8_11 · Cited by 4
Zhang, X., Huang, D., Pan, X., Si, Q., & You, Q.-Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1224381 · Cited by 4
“A combination of active chemotherapy, radiotherapy, targeted therapy, somatostatin analogues, and other multimodal treatments should be considered to minimize tumor size and prolong survival time (13).”
BackgroundBosch, E. M., Laskaratos, F., Sodergren, M. H., Faiz, O. D., & Humphries, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226877 · Cited by 4
“Primary tumours, despite their small size, may cause an extensive fibrotic reaction in the small bowel involving the lymph nodes and mesentery, leading to potential mesenteric ischemia and small-bowel obstruction [13–15].”
Laroia, S. T., Sasturkar, S. V., Rastogi, A., & Pamecha, V. (2014) · Indian Journal of Nuclear Medicine · doi:10.4103/0972-3919.147535 · Cited by 4
“[11] The chances of lymph nodal spread of the disease is seen in almost 60% of small bowel primary NET’s.”
BackgroundInfluentialMcKenzie, S. P., Lee, W., Artinyan, A., Mailey, B. A., Pigazzi, A., Ellenhorn, J. D. I., & Kim, J. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1225-8 · Cited by 4
Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
Oommen, R., Verma, P., Chanadana, Hephzibah, J., & Shanthly, N. (2012) · Indian Journal of Nuclear Medicine · doi:10.4103/0972-3919.115396 · Cited by 4
Metadata
- Authors
- Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
- Affiliations
- St Bartholomew's Hospital (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 458-511
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2031301095
- Semantic Scholar
- b09a37699a89446c4662f1bc87eb975bf31118b7
- Cited by
- 674
- References
- 670
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
- MeSH terms
- Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.